Download Free Assessing And Reducing Product Portfolio Complexity In The Pharmaceutical Industry Book in PDF and EPUB Free Download. You can read online Assessing And Reducing Product Portfolio Complexity In The Pharmaceutical Industry and write the review.

Overly complex product portfolios lead to inefficient use of resources and limit an organization's ability to react quickly to changing market dynamics. The challenges of reducing portfolio complexity are defining excess complexity, identifying it in the portfolio, and removing it while still delivering value to customers. Novartis Pharmaceuticals, in agreement with the prevalent operational excellence culture, is exploring complexity reduction as a mechanism to reduce waste, costs, and inventory levels. This thesis proposes the use of a comprehensive complexity reduction approach which targets both large and tail-end products for rationalization. The first complexity reduction focus area, redundant product rationalization, targets medium to large stock keeping units that do not directly satisfy a unique customer requirement. Removing redundant products has two benefits. First, larger products consume more resources, so the cost savings associated with removing a large redundant product are greater than that of smaller products. Second, sales levels will be preserved, as the demand for the rationalized product will shift to the remaining products that still meet the customer requirement in question. The second focus area is the more traditional tail-end pruning. By removing smaller, less profitable products and product groups, critical resources can be reallocated to more profitable products or new product launches. Novartis has piloted and partially implemented this approach with impressive results. With the support of influential leaders across all functions, Novartis is expecting a reduction of 15% of the portfolio in terms of number of finished product stock keeping units and a reduction of up to $22 million USD in inventory value. Other benefits include improvements in demand forecast accuracy, production write-offs, asset utilization, and replenishment lead times.
Michael Marti presents a complexity management model that is based on the reasoning that product architecture determines to a considerable extent how external complexity is translated into physical products. The model demonstrates a procedure to optimize a product’s architecture and is applied to several industrial products.
Knowledge-intensive product realization implies embedded intelligence; meaning that if both theoretical and practical knowledge and understanding of a subject is integrated into the design and production processes of products, this will significantly increase added value. This book presents papers accepted for the 9th Swedish Production Symposium (SPS2020), hosted by the School of Engineering, Jönköping University, Sweden, and held online on 7 & 8 October 2020 because of restrictions due to the Corona virus pandemic. The subtitle of the conference was Knowledge Intensive Product Realization in Co-Operation for Future Sustainable Competitiveness. The book contains the 57 papers accepted for presentation at the conference, and these are divided into nine sections which reflect the topics covered: resource efficient production; flexible production; virtual production development; humans in production systems; circular production systems and maintenance; integrated product and production development; advanced and optimized components, materials and manufacturing; digitalization for smart products and services; and responsive and efficient operations and supply chains. In addition, the book presents five special sessions from the symposium: development of changeable and reconfigurable production systems; smart production system design and development; supply chain relocation; management of manufacturing digitalization; and additive manufacturing in the production system. The book will be of interest to all those working in the field of knowledge-intensive product realization.
Shed Revenue-Draining Complexity Costs by Thirty Percent! “This is an ambitious book packed with insight and fresh thinking. Separating good from bad complexity costs is a critical task facing companies today, and the authors provide a compelling roadmap for solving the problem.” Michael B. McCallister, President and CEO, Humana Inc. “Waging War on Complexity Costs examines an incredibly important and often overlooked aspect of business and organizations in general—regulators and government officials should read this book and take notice. Complexity dramatically increases costs and risk of failure. It is like a cancer that eats away at efficiency and profitability.” Andy Beal, Chairman and CEO, Beal Bank “This is by far the best and most useful explanation of how to address complexity in a business. Waging War on Complexity Costs frames the issue in a way that companies can finally tackle the problem—this book delivers.” Ahmad R. Chatila, CEO, MEMC Electronic Materials Inc. “This is the first book that really targets organizational complexity in a compelling way, making this a must-read for any organization that is looking to distance itself from the competition. After years of cost-cutting, many companies are realizing that they still don’t have a discernable cost advantage. This book provides the platform to achieve just that, by attacking the complexity that bogs them down.” Tom DiDonato, EVP Human Resources, American Eagle Outfitters, Inc. About the Book: Complexity costs are the single biggest determinant of your company’s cost competitiveness. For the past two decades the pursuit of growth has created massive complexity in processes, product portfolios, and organizations, adding costs that companies can ill afford. The only good news is that your competitors may be carrying as much complexity as you are. Learn how to eliminate this complexity, and you can create a tremendous cost advantage over your competition. In Waging War on Complexity Costs, Stephen Wilson and Andrei Perumal deliver a powerful and practical approach for reclaiming your cost advantage. This executive-level resource presents a wealth of insight and new research to definitively answer key questions such as: How can I quantify the cost of complexity without getting lost in a sea of data? Where are the biggest opportunities for reducing product, process, and organizational complexity, and how can I cut through the interdependencies that trap these costs? How can I see results quickly by taking targeted actions against key levers? How do I keep complexity costs at bay? It is not enough to attack bloated product portfolios. Substantive cost improvements require addressing the complexity in the underlying processes and organizational structures. Waging War on Complexity Costs provides a wealth of relevant case studies with examples from Kraft, Tesco, Fiat, and the U.S. Navy and highlights specific strategies for reducing costs by 15-30% in significant portions of your business. Tomorrow’s consumers are emerging as wellinformed customers who know what they want and the price they’re willing to pay for it. Complexity not only drives costs; it creates a barrier between you and the customer. Declare a war on complexity costs and prepare for profitable growth.
The pharmaceutical industry is one of today’s most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders (from investors to doctors), multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. In this volume, the editors showcase contributions from experts around the world to capture the state of the art in research, analysis, and practice, and covering the full spectrum of topics relating to innovation and marketing, including R&D, promotion, pricing, branding, competitive strategy, and portfolio management. Chapters include such features as: · An extensive literature review, including coverage of research from fields other than marketing · an overview of how practitioners have addressed the topic · introduction of relevant analytical tools, such as statistics and ethnographic studies · suggestions for further research by scholars and students The result is a comprehensive, state-of-the-art resource that will be of interest to researchers, policymakers, and practitioners, alike.
This open access book provides insight into the implementation of Life Cycle approaches along the entire business value chain, supporting environmental, social and economic sustainability related to the development of industrial technologies, products, services and policies; and the development and management of smart agricultural systems, smart mobility systems, urban infrastructures and energy for the built environment. The book is based on papers presented at the 8th International Life Cycle Management Conference that took place from September 3-6, 2017 in Luxembourg, and which was organized by the Luxembourg Institute of Science and Technology (LIST) and the University of Luxembourg in the framework of the LCM Conference Series.
Supply chain performance will be a key indicator of overall corporate success into the next century. This book, edited by logistics and supply chain expert John Gattorna, and with international contributions, presents unpublished material on next generation thinking about the management of the supply chain. Based on the recently developed strategic alignment model it shows how external market dynamics, the company’s strategic response, and internal capability must be aligned if competitive advantage is to be achieved. Supply chain management is a strategic challenge demanding top level management attention. This book tackles the subject at that strategic level to help companies reposition their supply chains successfully. The book then offers the vital link between strategy setting and implementation, providing comprehensive coverage of the main areas of execution, and making it an essential compendium on all aspects of the subject. With case studies from major organizations from around the world, it is a ’must’ read for anyone wishing to be at the forefront of international supply chain management thinking. Strategic Supply Chain Alignment brings together for the first time the world’s leading logistics professionals, management consultants and academics to offer their insights and experiences on the latest supply chain management techniques. This collection of previously unpublished material offers the reader a unique opportunity to identify the hot issues, discover emerging strategies and uncover key industry and market perspectives. Divided into five sections which reflect the important components of the strategic alignment model, the book covers: The market: Customer value creation and segmentation, and the rationale behind the integration of supply with demand. Strategic response: Considers channel strategy, supply chain configuration and operations and distribution management. Culture: Adopting organization options which focus on delivering.
With crisp and insightful contributions from 47 of the world’s leading experts in various facets of retailing, Retailing in the 21st Century offers in one book a compendium of state-of-the-art, cutting-edge knowledge to guide successful retailing in the new millennium. In our competitive world, retailing is an exciting, complex and critical sector of business in most developed as well as emerging economies. Today, the retailing industry is being buffeted by a number of forces simultaneously, for example the growth of online retailing and the advent of ‘radio frequency identification’ (RFID) technology. Making sense of it all is not easy but of vital importance to retailing practitioners, analysts and policymakers.
On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical techniques, and drug product development. The workshop addressed these challenges broadly across the biologics domain but focused particularly on drug categories of greatest FDA and industrial interest such as monoclonal antibodies and vaccines. This publication summarizes the presentations and discussions from the workshop.
Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world.